Cleveland, Ohio From the Department of Plastic Surgery, Cleveland Clinic.
Plast Reconstr Surg. 2010 Jul;126(1):308-315. doi: 10.1097/PRS.0b013e3181dcb6f4.
From its origination involving successful rat hind-limb allograft studies using cyclosporine, face and upper extremity composite tissue allotransplantation has since developed into an exciting and promising subset of reconstructive transplant surgery. Current surgical technique involving composite tissue allotransplantation has allowed optimal outcomes in patients with massive facial and/or upper extremity defects; however, with its coexisting immunologic barrier, obligatory lifelong immunosuppression commits each patient to a daily risk of transplant-related complications with many unanswered questions. Since 1998, nearly 50 hand transplantations in 40 patients have been performed around the world at various levels ranging from wrist level to shoulder level. However, the risk-to-benefit ratio remains controversial in bilateral versus unilateral transplantation and has yet to be determined. From recent experience, the two most important determinants of the success of each patient's upper extremity transplant are patient compliance and intense rehabilitation. A total of nine face transplants have been performed since 2005. Multiple aesthetic subunits (i.e., nose, lips, eyelids) with or without underlying craniofacial skeletal defects (i.e., maxilla, mandible) have been successfully restored, thereby providing restoration of vital facial functions (i.e., smiling) in an unprecedented manner. As of today, face transplantation carries an estimated 2-year mortality of 20 percent. Concomitant composite tissue allotransplantation, which involves a variable combination of allograft subtypes, has been performed in two of the nine face transplant patients. These have included simultaneous bilateral hand transplants and tongue with mandible. Future study is warranted to investigate the potential advantages and disadvantages of using this approach versus a staged approach for reconstruction.
自成功开展环孢素治疗大鼠后肢同种异体移植的研究以来,面部和上肢复合组织同种异体移植已发展成为重建移植手术中令人兴奋且有前途的亚类。目前,涉及复合组织同种异体移植的外科技术已使大量面部和/或上肢缺损患者获得了最佳结果;然而,由于存在免疫障碍,每个患者都必须终身接受免疫抑制治疗,这使他们每天都面临移植相关并发症的风险,且存在许多尚未解答的问题。自 1998 年以来,全球范围内在不同层面(从腕关节到肩关节)对 40 名患者进行了近 50 例手部移植。然而,在双侧与单侧移植的风险-效益比方面仍存在争议,尚待确定。根据最近的经验,每位患者上肢移植成功的两个最重要决定因素是患者的依从性和强化康复。自 2005 年以来,已完成了总共 9 例面部移植。已成功恢复了多个美学亚单位(即鼻子、嘴唇、眼睑),以及是否存在颅面骨骼缺陷(即上颌骨、下颌骨),从而以前所未有的方式恢复了重要的面部功能(即微笑)。截至今日,面部移植的估计 2 年死亡率为 20%。同时进行的复合组织同种异体移植涉及同种异体移植亚类的可变组合,在 9 例面部移植患者中的 2 例中进行了同时双侧手部移植和舌与下颌骨移植。未来的研究需要调查使用这种方法与分期方法进行重建的潜在优缺点。